Fengzhi Li

USPTO Granted Patents = 8 (Patent Applications = 2)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 2.2

ph-index = 2

Forward Citations = 8(Granted Patents)

Location History:

Williamsville, NY (US) (2016)
Buffalo, NY (US) (2009 - 2021)

Company Filing History:

4 out of 310

Health Research, Inc.

patents

3 out of 3

Canget Biotek Pharma LLC

patents

1 out of 1,993

The State University of New York

patents

4. 1 out of 1

Ganget Biotekpharma, LLC

patent

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12268682 - Anticancer drug FL118 formulation for treatment of human cancer (2025-04-08),

2. 12187735 - Matter of composition, synthesis, formulation and application of FL118 platform positions 7 and 9-derived analogues for treatment of human disease (2025-01-07),

3. 11084828 - Use of the FL118 core chemical structure platform to generate FL118 derivatives for treatment of human disease (2021-08-10),

4. 10344037 - Use of the FL-one hundred eighteen core chemical structure platform to generate FL-one hundred eighteen derivatives for treatment of human disease (2019-07-09),

5. 9422303 - Formulations of water-insoluble chemical compounds and methods of using a formulation of compound FL118 for cancer therapy (2016-08-23),

6. 8043815 - Methods for analysis of PDEF and survivin as interconnected cancer biomarkers and targets for personalized medicine (2011-10-25),

7. 7968708 - Azepans and methods for making and using same (2011-06-28),

8. 7569221 - Compositions and methods for identifying agents that alter expression of survivin (2009-08-04),

Title: The Innovative Contributions of Fengzhi Li

Introduction

Fengzhi Li is a prominent inventor based in Buffalo, NY (US), known for his significant contributions to the field of cancer treatment. With a total of 8 patents, he has dedicated his research to developing novel formulations aimed at combating human cancer.

Latest Patents

Li's latest patents include groundbreaking work on the anticancer drug FL118. One of his notable inventions is the formulation of FL118 for the treatment of human cancer, which describes newly discovered formulations designed to preclude, eliminate, or reverse cancer phenotypes and treatment resistance. Additionally, he has developed methods related to the chemical synthesis and application of FL118 platform-derived analogues, which target multiple cellular proteins and their signaling pathways. This innovative approach aims to realize unique personalized cancer treatment through the application of structural relevant individual FL118 platform-derived analogues.

Career Highlights

Throughout his career, Fengzhi Li has worked with various organizations, including Health Research, Inc. and Canget Biotek Pharma LLC. His work has been instrumental in advancing cancer treatment methodologies and enhancing the understanding of personalized medicine.

Collaborations

Li has collaborated with notable colleagues, including Xiang Ling and David G Hangauer, contributing to the collective effort in cancer research and treatment innovation.

Conclusion

Fengzhi Li's innovative work in cancer treatment through the development of FL118 formulations showcases his commitment to advancing medical science. His contributions are paving the way for more effective and personalized cancer therapies.

This text is generated by artificial intelligence and may not be accurate.